Skip to main content
Erschienen in: Current Oncology Reports 5/2012

01.10.2012 | Lymphomas (PA Hamlin, Section Editor)

NK/T-Cell Lymphomas: Pathobiology, Prognosis and Treatment Paradigm

verfasst von: Ritsuro Suzuki

Erschienen in: Current Oncology Reports | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

The current World Health Organization (WHO) classification includes two types of natural killer (NK)-cell lymphomas: extranodal NK/T-cell lymphoma, nasal type (ENKL), and aggressive NK-cell leukemia (ANKL). These diseases are mostly endemic to East Asia and Latin America. The Epstein–Barr virus (EBV) is usually detected in tumor cells, suggesting that EBV plays an important role in lymphomagenesis. At the site of origin, ENKL can be divided into two major subtypes: nasal and extranasal diseases. The advanced disease presentation, highly aggressive clinical course, and poor prognosis of the latter are analogous to ANKL. It is well known that P-glycoprotein, which is a product of the multi-drug resistance (MDR1) gene, is expressed on neoplastic cells of ENKL or ANKL. This is a major cause of the refractoriness of malignant lymphoma to conventional chemotherapeutic regimens containing anthracycline. Recent studies, however, have identified that L-asparaginase-containing regimens, such as SMILE (steroid, methotrexate, ifosfamide, L-asparaginase and etoposide), are effective for ENKL. Considering the myelotoxicity of SMILE, its use in the treatment of ANKL needs some modifications, but this treatment scheme is promising in improving the prognosis of NK-cell lymphomas.
Literatur
1.
Zurück zum Zitat Chan JKC, Quintanilla-Martinez L, Ferry JA, Peh S-C. Extranodal NK/T-cell lymphoma, nasal type. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC; 2008. p. 285–8. Chan JKC, Quintanilla-Martinez L, Ferry JA, Peh S-C. Extranodal NK/T-cell lymphoma, nasal type. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC; 2008. p. 285–8.
2.
Zurück zum Zitat Chan JKC, Jaffe ES, Ralfkiaer E, Ko Y-H. Aggressive NK-cell leukemia. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC; 2008. p. 276–7. Chan JKC, Jaffe ES, Ralfkiaer E, Ko Y-H. Aggressive NK-cell leukemia. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC; 2008. p. 276–7.
3.
Zurück zum Zitat Yamaguchi M, Kita K, Miwa H, Nishii K, Oka K, Ohno T, et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer. 1995;76:2351–6.PubMedCrossRef Yamaguchi M, Kita K, Miwa H, Nishii K, Oka K, Ohno T, et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer. 1995;76:2351–6.PubMedCrossRef
4.
Zurück zum Zitat Egashira M, Kawamata N, Sugimoto K, Oshimi K. P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Blood. 1999;93:599–606.PubMed Egashira M, Kawamata N, Sugimoto K, Oshimi K. P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Blood. 1999;93:599–606.PubMed
5.
Zurück zum Zitat Trambas C, Wang Z, Cianfriglia M, Woods G. Evidence that natural killer cells express mini P-glycoproteins but not classic 170 kDa P-glycoprotein. Br J Haematol. 2001;114:177–18.PubMedCrossRef Trambas C, Wang Z, Cianfriglia M, Woods G. Evidence that natural killer cells express mini P-glycoproteins but not classic 170 kDa P-glycoprotein. Br J Haematol. 2001;114:177–18.PubMedCrossRef
6.
Zurück zum Zitat Suzuki R, Takeuchi K, Ohshima K, Nakamura S. Extranodal NK/T-cell lymphoma: diagnosis and treatment cues. Hematol Oncol. 2008;26:66–72.PubMedCrossRef Suzuki R, Takeuchi K, Ohshima K, Nakamura S. Extranodal NK/T-cell lymphoma: diagnosis and treatment cues. Hematol Oncol. 2008;26:66–72.PubMedCrossRef
7.
Zurück zum Zitat Kim SJ, Kim WS. Treatment of localized extranodal NK/T cell lymphoma, nasal type. Int J Hematol. 2010;92:690–6.PubMedCrossRef Kim SJ, Kim WS. Treatment of localized extranodal NK/T cell lymphoma, nasal type. Int J Hematol. 2010;92:690–6.PubMedCrossRef
8.
Zurück zum Zitat Suzuki R. Treatment of advanced extranodal NK/T cell lymphoma, nasal-type and aggressive NK-cell leukemia. Int J Hematol. 2010;92:697–701.PubMedCrossRef Suzuki R. Treatment of advanced extranodal NK/T cell lymphoma, nasal-type and aggressive NK-cell leukemia. Int J Hematol. 2010;92:697–701.PubMedCrossRef
9.
Zurück zum Zitat Hercend T, Schmidt RE. Characteristics and uses of natural killer cells. Immunol Today. 1998;9:291–3.CrossRef Hercend T, Schmidt RE. Characteristics and uses of natural killer cells. Immunol Today. 1998;9:291–3.CrossRef
10.
Zurück zum Zitat Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood. 1990;76:2421–38.PubMed Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood. 1990;76:2421–38.PubMed
11.
Zurück zum Zitat Sanchez MJ, Muench MO, Roncarolo MG, Lanier LL, Phillips JH. Identification of a common T/natural killer cell progenitor in human fetal thymus. J Exp Med. 1994;180:569–76.PubMedCrossRef Sanchez MJ, Muench MO, Roncarolo MG, Lanier LL, Phillips JH. Identification of a common T/natural killer cell progenitor in human fetal thymus. J Exp Med. 1994;180:569–76.PubMedCrossRef
12.
Zurück zum Zitat Shibuya A, Nagayoshi K, Nakamura K, Nakauchi H. Lymphokine requirement for the generation of natural killer cells from CD34þ hematopoietic progenitor cells. Blood. 1995;85:3538–46.PubMed Shibuya A, Nagayoshi K, Nakamura K, Nakauchi H. Lymphokine requirement for the generation of natural killer cells from CD34þ hematopoietic progenitor cells. Blood. 1995;85:3538–46.PubMed
13.
Zurück zum Zitat Ishii Y, Yamanaka N, Ogawa K, Yoshida Y, Takami T, Matsuura A, et al. Nasal T-cell lymphoma as a type of so-called "lethal midline granuloma". Cancer. 1982;50:2336–44.PubMedCrossRef Ishii Y, Yamanaka N, Ogawa K, Yoshida Y, Takami T, Matsuura A, et al. Nasal T-cell lymphoma as a type of so-called "lethal midline granuloma". Cancer. 1982;50:2336–44.PubMedCrossRef
14.
Zurück zum Zitat Jaffe ES, Chan JKC, Su I-J, Frizzera G, Mori S, Feller AC, et al. Report of the workshop on nasal and related extranodal angiocentric T/natural killer cell lymphomas. Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol. 1996;20:103–11.PubMedCrossRef Jaffe ES, Chan JKC, Su I-J, Frizzera G, Mori S, Feller AC, et al. Report of the workshop on nasal and related extranodal angiocentric T/natural killer cell lymphomas. Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol. 1996;20:103–11.PubMedCrossRef
15.
Zurück zum Zitat Suzumiya J, Takeshita M, Kimura N, Kikuchi M, Uchida T, Hisano S, et al. Expression of adult and fetal natural killer cell markers in sinonasal lymphomas. Blood. 1994;83:2255–60.PubMed Suzumiya J, Takeshita M, Kimura N, Kikuchi M, Uchida T, Hisano S, et al. Expression of adult and fetal natural killer cell markers in sinonasal lymphomas. Blood. 1994;83:2255–60.PubMed
16.
Zurück zum Zitat Emile J-F, Boulland M-L, Haioun C, Kanavaros P, Petrella T, Delfau-Larue MH, et al. CD5- CD56+ T-cell receptor silent peripheral T-cell lymphomas are natural killer cell lymphomas. Blood. 1996;87:1466–73.PubMed Emile J-F, Boulland M-L, Haioun C, Kanavaros P, Petrella T, Delfau-Larue MH, et al. CD5- CD56+ T-cell receptor silent peripheral T-cell lymphomas are natural killer cell lymphomas. Blood. 1996;87:1466–73.PubMed
17.
Zurück zum Zitat Ohshima K, Suzumiya J, Shimazaki K, Kato A, Tanaka T, Kanda M, et al. Nasal T/NK cell lymphomas commonly express perforin and Fas ligand: important mediators of tissue damage. Histopathology. 1997;31:444–50.PubMedCrossRef Ohshima K, Suzumiya J, Shimazaki K, Kato A, Tanaka T, Kanda M, et al. Nasal T/NK cell lymphomas commonly express perforin and Fas ligand: important mediators of tissue damage. Histopathology. 1997;31:444–50.PubMedCrossRef
18.
Zurück zum Zitat Mori N, Yatabe Y, Oka K, Kinoshita T, Kobayashi T, Ono T, et al. Expression of perforin in nasal lymphoma. Am J Pathol. 1996;149:699–705.PubMed Mori N, Yatabe Y, Oka K, Kinoshita T, Kobayashi T, Ono T, et al. Expression of perforin in nasal lymphoma. Am J Pathol. 1996;149:699–705.PubMed
19.
Zurück zum Zitat Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting - Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835–49.PubMed Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting - Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835–49.PubMed
20.
Zurück zum Zitat Cheung MMC, Chan JKC, Lau WH, Foo W, Chan PT, Ng CS, Ngan RK. Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol. 1998;16:70–7.PubMed Cheung MMC, Chan JKC, Lau WH, Foo W, Chan PT, Ng CS, Ngan RK. Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol. 1998;16:70–7.PubMed
21.
Zurück zum Zitat Kim GE, Koom WS, Yang WI, Lee SW, Keum KC, Lee CG, Suh CO, Hahn JS, Roh JK, Kim JH. Clinical relevance of three subtypes of primary sinonasal lymphoma characterized by immunophenotypic analysis. Head Neck. 2004;26:584–93.PubMedCrossRef Kim GE, Koom WS, Yang WI, Lee SW, Keum KC, Lee CG, Suh CO, Hahn JS, Roh JK, Kim JH. Clinical relevance of three subtypes of primary sinonasal lymphoma characterized by immunophenotypic analysis. Head Neck. 2004;26:584–93.PubMedCrossRef
22.
Zurück zum Zitat Harabuchi Y, Yamanaka N, Kataura A, Imai S, Kinoshita T, Mizuno F, Osato T. Epstein–Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet. 1990;335:128–30.PubMedCrossRef Harabuchi Y, Yamanaka N, Kataura A, Imai S, Kinoshita T, Mizuno F, Osato T. Epstein–Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet. 1990;335:128–30.PubMedCrossRef
23.
Zurück zum Zitat Kawa K. Epstein–Barr virus–associated diseases in humans. Int J Hematol. 2000;71:108–17.PubMed Kawa K. Epstein–Barr virus–associated diseases in humans. Int J Hematol. 2000;71:108–17.PubMed
24.
Zurück zum Zitat Wong KF, Chan JK, Kwong YL. Identification of del(6)(q21q25) as a recurring chromosomal abnormality in putative NK cell lymphoma/leukaemia. Br J Haematol. 1997;98:922–6.PubMedCrossRef Wong KF, Chan JK, Kwong YL. Identification of del(6)(q21q25) as a recurring chromosomal abnormality in putative NK cell lymphoma/leukaemia. Br J Haematol. 1997;98:922–6.PubMedCrossRef
25.
Zurück zum Zitat Tien HF, Su IJ, Tang JL, Liu MC, Lee FY, Chen YC, Chuang SM. Clonal chromosomal abnormalities as direct evidence for clonality in nasal T/natural killer cell lymphomas. Br J Haematol. 1997;97:621–5.PubMedCrossRef Tien HF, Su IJ, Tang JL, Liu MC, Lee FY, Chen YC, Chuang SM. Clonal chromosomal abnormalities as direct evidence for clonality in nasal T/natural killer cell lymphomas. Br J Haematol. 1997;97:621–5.PubMedCrossRef
26.
Zurück zum Zitat Suzuki R, Suzumiya J, Nakamura S, Aoki S, Notoya A, Ozaki S, et al. Aggressive natural killer (NK)-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia. 2004;18:763–70.PubMedCrossRef Suzuki R, Suzumiya J, Nakamura S, Aoki S, Notoya A, Ozaki S, et al. Aggressive natural killer (NK)-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia. 2004;18:763–70.PubMedCrossRef
27.
Zurück zum Zitat Nakashima Y, Tagawa H, Suzuki R, Karnan S, Karube K, Ohshima K, Muta K, Nawata H, Morishima Y, Nakamura S, Seto M. Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma/leukemia: different genomic alteration patterns of aggressive NK-cell leukemia and extranodal NK/T-cell lymphoma, nasal type. Genes Chromosomes Cancer. 2005;44:247–55.PubMedCrossRef Nakashima Y, Tagawa H, Suzuki R, Karnan S, Karube K, Ohshima K, Muta K, Nawata H, Morishima Y, Nakamura S, Seto M. Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma/leukemia: different genomic alteration patterns of aggressive NK-cell leukemia and extranodal NK/T-cell lymphoma, nasal type. Genes Chromosomes Cancer. 2005;44:247–55.PubMedCrossRef
28.
Zurück zum Zitat Iqbal J, Kucuk C, Deleeuw RJ, Srivastava G, Tam W, Geng H, Klinkebiel D, Christman JK, Patel K, Cao K, Shen L, Dybkaer K, Tsui IF, Ali H, Shimizu N, Au WY, Lam WL, Chan WC. Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies. Leukemia. 2009;23:1139–51.PubMedCrossRef Iqbal J, Kucuk C, Deleeuw RJ, Srivastava G, Tam W, Geng H, Klinkebiel D, Christman JK, Patel K, Cao K, Shen L, Dybkaer K, Tsui IF, Ali H, Shimizu N, Au WY, Lam WL, Chan WC. Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies. Leukemia. 2009;23:1139–51.PubMedCrossRef
29.
Zurück zum Zitat Karube K, Nakagawa M, Tsuzuki S, Takeuchi I, Honma K, Nakashima Y, Shimizu N, Ko YH, Morishima Y, Ohshima K, Nakamura S, Seto M. Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses. Blood. 2011;118:3195–204.PubMedCrossRef Karube K, Nakagawa M, Tsuzuki S, Takeuchi I, Honma K, Nakashima Y, Shimizu N, Ko YH, Morishima Y, Ohshima K, Nakamura S, Seto M. Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses. Blood. 2011;118:3195–204.PubMedCrossRef
30.
Zurück zum Zitat Küçük C, Iqbal J, Hu X, Gaulard P, De Leval L, Srivastava G, Au WY, McKeithan TW, Chan WC. PRDM1 is a tumor suppressor gene in natural killer cell malignancies. Proc Natl Acad Sci USA. 2011;108:20119–24.PubMedCrossRef Küçük C, Iqbal J, Hu X, Gaulard P, De Leval L, Srivastava G, Au WY, McKeithan TW, Chan WC. PRDM1 is a tumor suppressor gene in natural killer cell malignancies. Proc Natl Acad Sci USA. 2011;108:20119–24.PubMedCrossRef
31.
Zurück zum Zitat Pasqualucci L, Compagno M, Houldsworth J, Monti S, Grunn A, Nandula SV, Aster JC, Murty VV, Shipp MA, Dalla-Favera R. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med. 2006;203:311–7.PubMedCrossRef Pasqualucci L, Compagno M, Houldsworth J, Monti S, Grunn A, Nandula SV, Aster JC, Murty VV, Shipp MA, Dalla-Favera R. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med. 2006;203:311–7.PubMedCrossRef
32.
Zurück zum Zitat Tam W, Gomez M, Chadburn A, Lee JW, Chan WC, Knowles DM. Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. Blood. 2006;107:4090–100.PubMedCrossRef Tam W, Gomez M, Chadburn A, Lee JW, Chan WC, Knowles DM. Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. Blood. 2006;107:4090–100.PubMedCrossRef
33.
Zurück zum Zitat Sakajiri S, Kawamata N, Egashira M, Mori K, Oshimi K. Molecular analysis of tumor suppressor genes, Rb, p53, p16INK4A, p15INK4B and p14ARF in natural killer cell neoplasms. Jpn J Cancer Res. 2001;92:1048–56.PubMedCrossRef Sakajiri S, Kawamata N, Egashira M, Mori K, Oshimi K. Molecular analysis of tumor suppressor genes, Rb, p53, p16INK4A, p15INK4B and p14ARF in natural killer cell neoplasms. Jpn J Cancer Res. 2001;92:1048–56.PubMedCrossRef
34.
Zurück zum Zitat Quintanilla-Martinez L, Kremer M, Keller G, Nathrath M, Gamboa-Dominguez A, Meneses A, Luna-Contreras L, Cabras A, Hoefler H, Mohar A, Fend F. p53 Mutations in nasal natural killer/T-cell lymphoma from Mexico: association with large cell morphology and advanced disease. Am J Pathol. 2001;159:2095–105.PubMedCrossRef Quintanilla-Martinez L, Kremer M, Keller G, Nathrath M, Gamboa-Dominguez A, Meneses A, Luna-Contreras L, Cabras A, Hoefler H, Mohar A, Fend F. p53 Mutations in nasal natural killer/T-cell lymphoma from Mexico: association with large cell morphology and advanced disease. Am J Pathol. 2001;159:2095–105.PubMedCrossRef
35.
Zurück zum Zitat Suzuki R, Suzumiya J, Yamaguchi M, Nakamura S, Kameoka J, Kojima H, Abe M, Kinoshita T, Yoshino T, Iwatsuki K, Kagami Y, Tsuzuki T, Kurokawa M, Ito K, Kawa K, Oshimi K. Prognostic factors for mature natural killer (NK)-cell neoplasms: aggressive NK-cell leukemia and extranodal NK-cell lymphoma, nasal-type. Ann Oncol. 2010;21:1032–40.PubMedCrossRef Suzuki R, Suzumiya J, Yamaguchi M, Nakamura S, Kameoka J, Kojima H, Abe M, Kinoshita T, Yoshino T, Iwatsuki K, Kagami Y, Tsuzuki T, Kurokawa M, Ito K, Kawa K, Oshimi K. Prognostic factors for mature natural killer (NK)-cell neoplasms: aggressive NK-cell leukemia and extranodal NK-cell lymphoma, nasal-type. Ann Oncol. 2010;21:1032–40.PubMedCrossRef
36.
Zurück zum Zitat Chim CS, Ma SY, Au WY, Choy C, Lie AK, Liang R, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the international prognostic index. Blood. 2004;103:216–21.PubMedCrossRef Chim CS, Ma SY, Au WY, Choy C, Lie AK, Liang R, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the international prognostic index. Blood. 2004;103:216–21.PubMedCrossRef
37.
Zurück zum Zitat Kim TM, Park YH, Lee SY, Kim JH, Kim DW, Im SA, et al. Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage IE/IIE extranodal NK/T-cell lymphoma, nasal type. Blood. 2005;106:3785–90.PubMedCrossRef Kim TM, Park YH, Lee SY, Kim JH, Kim DW, Im SA, et al. Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage IE/IIE extranodal NK/T-cell lymphoma, nasal type. Blood. 2005;106:3785–90.PubMedCrossRef
38.
Zurück zum Zitat Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006;24:612–8.PubMedCrossRef Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006;24:612–8.PubMedCrossRef
39.
Zurück zum Zitat Li YX, Coucke PA, Li JY, Gu DZ, Liu XF, Zhou LQ, Mirimanoff RO, Yu ZH, Huang YR. Primary non-Hodgkin's lymphoma of the nasal cavity: prognostic significance of paranasal extension and the role of radiotherapy and chemotherapy. Cancer. 1998;83:449–56.PubMedCrossRef Li YX, Coucke PA, Li JY, Gu DZ, Liu XF, Zhou LQ, Mirimanoff RO, Yu ZH, Huang YR. Primary non-Hodgkin's lymphoma of the nasal cavity: prognostic significance of paranasal extension and the role of radiotherapy and chemotherapy. Cancer. 1998;83:449–56.PubMedCrossRef
40.
Zurück zum Zitat Li CC, Tien HF, Tang JL, Yao M, Chen YC, Su IJ, et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer. 2004;100:366–75.PubMedCrossRef Li CC, Tien HF, Tang JL, Yao M, Chen YC, Su IJ, et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer. 2004;100:366–75.PubMedCrossRef
41.
Zurück zum Zitat Ng SB, Lai KW, Murugaya S, Lee KM, Loong SL, Fook-Chong S, Tao M, Sng I. Nasal-type extranodal natural killer/T-cell lymphomas: a clinicopathologic and genotypic study of 42 cases in Singapore. Mod Pathol. 2004;17:1097–107.PubMedCrossRef Ng SB, Lai KW, Murugaya S, Lee KM, Loong SL, Fook-Chong S, Tao M, Sng I. Nasal-type extranodal natural killer/T-cell lymphomas: a clinicopathologic and genotypic study of 42 cases in Singapore. Mod Pathol. 2004;17:1097–107.PubMedCrossRef
42.
Zurück zum Zitat Ahn HK, Suh C, Chuang SS, Suzumiya J, Ko YH, Kim SJ, Huh JR, Yoon DH, Oh SY, Kim JS, Lee SI, Park KW, Hsieh PP, Nakamura S, Yoshino T, Ito K, Nagatani T, Oshimi K, Suzuki R, Kim WS. Extranodal natural killer/T cell lymphoma from skin or soft tissue: suggestion of treatment from multinational retrospective analysis. Ann Oncol (in press) Ahn HK, Suh C, Chuang SS, Suzumiya J, Ko YH, Kim SJ, Huh JR, Yoon DH, Oh SY, Kim JS, Lee SI, Park KW, Hsieh PP, Nakamura S, Yoshino T, Ito K, Nagatani T, Oshimi K, Suzuki R, Kim WS. Extranodal natural killer/T cell lymphoma from skin or soft tissue: suggestion of treatment from multinational retrospective analysis. Ann Oncol (in press)
43.
Zurück zum Zitat Au WY, Weisenburger DD, Intragumtornchai T, Nakamura S, Kim WS, Sng I, Vose J, Armitage JO, Liang R. Clinical differences between nasal and extranasal NK/T-cell lymphoma: a study of 136 cases from the International Peripheral T-cell Lymphoma Project. Blood. 2009;113:3931–7.PubMedCrossRef Au WY, Weisenburger DD, Intragumtornchai T, Nakamura S, Kim WS, Sng I, Vose J, Armitage JO, Liang R. Clinical differences between nasal and extranasal NK/T-cell lymphoma: a study of 136 cases from the International Peripheral T-cell Lymphoma Project. Blood. 2009;113:3931–7.PubMedCrossRef
44.
Zurück zum Zitat Suzuki R, Suzumiya J, Oshimi K. Differences between nasal and extra-nasal NK/T-cell lymphoma. Blood. 2009;113:6260–1.PubMedCrossRef Suzuki R, Suzumiya J, Oshimi K. Differences between nasal and extra-nasal NK/T-cell lymphoma. Blood. 2009;113:6260–1.PubMedCrossRef
45.
Zurück zum Zitat Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117:5019–32.PubMedCrossRef Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117:5019–32.PubMedCrossRef
46.
Zurück zum Zitat Dennis Lo YM, Chan WY, Ng EKW, Chan LYS, Lai PBS, Tam JS, Sydney Chung SC. Circulating Epstein–Barr virus DNA in the serum of patients with gastric carcinoma. Clin Cancer Res. 2001;7:1856–9. Dennis Lo YM, Chan WY, Ng EKW, Chan LYS, Lai PBS, Tam JS, Sydney Chung SC. Circulating Epstein–Barr virus DNA in the serum of patients with gastric carcinoma. Clin Cancer Res. 2001;7:1856–9.
47.
Zurück zum Zitat Chan KCA, Zhang J, Chan ATC, Lei KIK, Leung S-F, Chan LYS, Chow KCK, Lo YMD. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res. 2003;63:2028–32.PubMed Chan KCA, Zhang J, Chan ATC, Lei KIK, Leung S-F, Chan LYS, Chow KCK, Lo YMD. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res. 2003;63:2028–32.PubMed
48.
Zurück zum Zitat Au WY, Pang A, Choy C, Chim CS, Kwong YL. Quantification of circulating Epstein–Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood. 2004;104:243–9.PubMedCrossRef Au WY, Pang A, Choy C, Chim CS, Kwong YL. Quantification of circulating Epstein–Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood. 2004;104:243–9.PubMedCrossRef
49.
Zurück zum Zitat • Suzuki R, Yamaguchi M, Izutsu K, Yamamoto G, Takada K, Harabuchi Y, Isobe Y, Gomyo H, Koike T, Okamoto M, Hyo R, Suzumiya J, Nakamura S, Kawa K, Oshimi K. Prospective measurement of Epstein–Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type. Blood. 2011;118:6018–22. Plasma EBV-DNA can predict tumor burden, response to treatment and prognosis of patients with ENKL. PubMedCrossRef • Suzuki R, Yamaguchi M, Izutsu K, Yamamoto G, Takada K, Harabuchi Y, Isobe Y, Gomyo H, Koike T, Okamoto M, Hyo R, Suzumiya J, Nakamura S, Kawa K, Oshimi K. Prospective measurement of Epstein–Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type. Blood. 2011;118:6018–22. Plasma EBV-DNA can predict tumor burden, response to treatment and prognosis of patients with ENKL. PubMedCrossRef
50.
Zurück zum Zitat Kimura H, Ito Y, Suzuki R, Nishiyama Y. Measuring Epstein–Barr virus (EBV) load: its significance and application in each EBV-associated disease. Rev Med Virol. 2008;18:305–19.PubMedCrossRef Kimura H, Ito Y, Suzuki R, Nishiyama Y. Measuring Epstein–Barr virus (EBV) load: its significance and application in each EBV-associated disease. Rev Med Virol. 2008;18:305–19.PubMedCrossRef
51.
Zurück zum Zitat Suzuki R, Kimura H, Kwong YL, Maeda Y, Hashimoto C, Kim WS, Suh C, Izutsu K, Ishida F, Ito Y, Yamaguchi M, Suzumiya J, Hyo R, Nakamura S, Oshimi K. Pretreatment EBV-DNA copy number is predictive for response to SMILE chemotherapy for newly-diagnosed stage IV, relapsed or refractory extranodal NK/T-cell lymphoma, nasal type: results of NKTSG phase II study. Blood. 2009;116:2873a [Abstract #2873]. Suzuki R, Kimura H, Kwong YL, Maeda Y, Hashimoto C, Kim WS, Suh C, Izutsu K, Ishida F, Ito Y, Yamaguchi M, Suzumiya J, Hyo R, Nakamura S, Oshimi K. Pretreatment EBV-DNA copy number is predictive for response to SMILE chemotherapy for newly-diagnosed stage IV, relapsed or refractory extranodal NK/T-cell lymphoma, nasal type: results of NKTSG phase II study. Blood. 2009;116:2873a [Abstract #2873].
52.
Zurück zum Zitat Kim GE, Cho JH, Yang WI, Chung EJ, Suh CO, Park KR, et al. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J Clin Oncol. 2000;18:54–63.PubMed Kim GE, Cho JH, Yang WI, Chung EJ, Suh CO, Park KR, et al. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J Clin Oncol. 2000;18:54–63.PubMed
53.
Zurück zum Zitat You JY, Chi KH, Yang MH, Chen CC, Ho CH, Chau WK, et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan. Ann Oncol. 2004;15:618–25.PubMedCrossRef You JY, Chi KH, Yang MH, Chen CC, Ho CH, Chau WK, et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan. Ann Oncol. 2004;15:618–25.PubMedCrossRef
54.
Zurück zum Zitat Kim SJ, Kim BS, Choi CW, Seo HY, Seol HR, Sung HJ, et al. Treatment outcome of front-line systemic chemotherapy for localized extranodal NK/T cell lymphoma in nasal and upper aerodigestive tract. Leuk Lymphoma. 2006;47:1265–73.PubMedCrossRef Kim SJ, Kim BS, Choi CW, Seo HY, Seol HR, Sung HJ, et al. Treatment outcome of front-line systemic chemotherapy for localized extranodal NK/T cell lymphoma in nasal and upper aerodigestive tract. Leuk Lymphoma. 2006;47:1265–73.PubMedCrossRef
55.
Zurück zum Zitat Wang B, Lu JJ, Ma X, Guo Y, Lu H, Hong X, et al. Combined chemotherapy and external beam radiation for stage IE and IIE natural killer T-cell lymphoma of nasal cavity. Leuk Lymphoma. 2007;48:396–402.PubMedCrossRef Wang B, Lu JJ, Ma X, Guo Y, Lu H, Hong X, et al. Combined chemotherapy and external beam radiation for stage IE and IIE natural killer T-cell lymphoma of nasal cavity. Leuk Lymphoma. 2007;48:396–402.PubMedCrossRef
56.
Zurück zum Zitat Li YX, Yao B, Jin J, Wang WH, Liu YP, Song YW, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol. 2006;24:181–9.PubMedCrossRef Li YX, Yao B, Jin J, Wang WH, Liu YP, Song YW, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol. 2006;24:181–9.PubMedCrossRef
57.
Zurück zum Zitat Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol. 2009;27:5594–600.PubMedCrossRef Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol. 2009;27:5594–600.PubMedCrossRef
58.
Zurück zum Zitat Kim SJ, Kim K, Kim BS, Kim CY, Suh C, Huh J, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma: Consortium for Improving Survival of Lymphoma Study. J Clin Oncol. 2009;27:6027–32.PubMedCrossRef Kim SJ, Kim K, Kim BS, Kim CY, Suh C, Huh J, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma: Consortium for Improving Survival of Lymphoma Study. J Clin Oncol. 2009;27:6027–32.PubMedCrossRef
59.
Zurück zum Zitat Au WY, Lie AK, Liang R, Kwong YL, Yau CC, Cheung MM, Ngan KC, Lau WH, Wong KH, Yiu HY, Cheng HC, Au KH, Chan JK. Autologous stem cell transplantation for nasal NK/T-cell lymphoma: a progress report on its value. Ann Oncol. 2003;14:1673–6.PubMedCrossRef Au WY, Lie AK, Liang R, Kwong YL, Yau CC, Cheung MM, Ngan KC, Lau WH, Wong KH, Yiu HY, Cheng HC, Au KH, Chan JK. Autologous stem cell transplantation for nasal NK/T-cell lymphoma: a progress report on its value. Ann Oncol. 2003;14:1673–6.PubMedCrossRef
60.
Zurück zum Zitat Suzuki R, Suzumiya J, Nakamura S, Kagami Y, Kameoka J, Sakai C, et al. Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms. Bone Marrow Transplant. 2006;37:425–31.PubMedCrossRef Suzuki R, Suzumiya J, Nakamura S, Kagami Y, Kameoka J, Sakai C, et al. Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms. Bone Marrow Transplant. 2006;37:425–31.PubMedCrossRef
61.
Zurück zum Zitat Kim HJ, Bang SM, Lee J, Kwon HC, Suh C, Kim HJ, et al. High-dose chemotherapy with autologous stem cell transplantation in extranodal NK/T-cell lymphoma: a retrospective comparison with non-transplantation cases. Bone Marrow Transplant. 2006;37:819–24.PubMedCrossRef Kim HJ, Bang SM, Lee J, Kwon HC, Suh C, Kim HJ, et al. High-dose chemotherapy with autologous stem cell transplantation in extranodal NK/T-cell lymphoma: a retrospective comparison with non-transplantation cases. Bone Marrow Transplant. 2006;37:819–24.PubMedCrossRef
62.
Zurück zum Zitat Lee J, Au WY, Park MJ, Suzumiya J, Nakamura S, Kameoka J, et al. Autologous hematopoietic stem cell transplantation in extranodal natural killer/T cell lymphoma: a multinational, multicenter, matched controlled study. Biol Blood Marrow Transplant. 2008;14:1356–64.PubMedCrossRef Lee J, Au WY, Park MJ, Suzumiya J, Nakamura S, Kameoka J, et al. Autologous hematopoietic stem cell transplantation in extranodal natural killer/T cell lymphoma: a multinational, multicenter, matched controlled study. Biol Blood Marrow Transplant. 2008;14:1356–64.PubMedCrossRef
63.
Zurück zum Zitat Suzuki R. Leukemia and lymphoma of natural killer cells. J Clin Exp Hematop. 2005;45:51–70.CrossRef Suzuki R. Leukemia and lymphoma of natural killer cells. J Clin Exp Hematop. 2005;45:51–70.CrossRef
64.
Zurück zum Zitat •• Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E, Suzumiya J, Kodama T, Kimura H, Hyo R, Nakamura S, Oshimi K, Suzuki R. Phase II study of SMILE chemotherapy for newly-diagnosed stage IV, relapsed or refractory extranodal NK/T-cell lymphoma, nasal type: The NK-cell Tumor Study Group (NKTSG) study. J Clin Oncol. 2011;29:4410–6. SMILE chemotherapy improves ORR, PFS and OS in patients with disseminated/relapsed/refractory ENKL. PubMedCrossRef •• Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E, Suzumiya J, Kodama T, Kimura H, Hyo R, Nakamura S, Oshimi K, Suzuki R. Phase II study of SMILE chemotherapy for newly-diagnosed stage IV, relapsed or refractory extranodal NK/T-cell lymphoma, nasal type: The NK-cell Tumor Study Group (NKTSG) study. J Clin Oncol. 2011;29:4410–6. SMILE chemotherapy improves ORR, PFS and OS in patients with disseminated/relapsed/refractory ENKL. PubMedCrossRef
65.
Zurück zum Zitat Yong W, Zheng W, Zhang Y, Zhu J, Wei Y, Zhu D, et al. L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Int J Hematol. 2003;78:163–7.PubMedCrossRef Yong W, Zheng W, Zhang Y, Zhu J, Wei Y, Zhu D, et al. L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Int J Hematol. 2003;78:163–7.PubMedCrossRef
66.
Zurück zum Zitat Jaccard A, Petit B, Girault S, Suarez F, Gressin R, Zini JM, Coiteux V, Larroche C, Devidas A, Thiéblemont C, Gaulard P, Marin B, Gachard N, Bordessoule D, Hermine O. L-Asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature. Ann Oncol. 2009;20:110–6.PubMedCrossRef Jaccard A, Petit B, Girault S, Suarez F, Gressin R, Zini JM, Coiteux V, Larroche C, Devidas A, Thiéblemont C, Gaulard P, Marin B, Gachard N, Bordessoule D, Hermine O. L-Asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature. Ann Oncol. 2009;20:110–6.PubMedCrossRef
67.
Zurück zum Zitat Jaccard A, Gachard N, Marin B, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase II study. Blood. 2011;117:1834–9.PubMedCrossRef Jaccard A, Gachard N, Marin B, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase II study. Blood. 2011;117:1834–9.PubMedCrossRef
68.
Zurück zum Zitat Murashige N, Kami M, Kishi Y, Kim S-W, Takeuchi M, Matsue K, et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol. 2005;130:561–7.PubMedCrossRef Murashige N, Kami M, Kishi Y, Kim S-W, Takeuchi M, Matsue K, et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol. 2005;130:561–7.PubMedCrossRef
69.
Zurück zum Zitat Suzuki R, Kako S, Hyo R, Izutsu K, Ito T, Shinagawa K, Endo T, Sakamaki H, Suzumiya J. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for extranodal NK/T-cell lymphoma, nasal-type: Analysis of The Japan Society for Hematopoietic Cell Transplantation (JSHCT) Lymphoma Working Group. Blood. 2011;118:503a [Abstract #503]. Suzuki R, Kako S, Hyo R, Izutsu K, Ito T, Shinagawa K, Endo T, Sakamaki H, Suzumiya J. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for extranodal NK/T-cell lymphoma, nasal-type: Analysis of The Japan Society for Hematopoietic Cell Transplantation (JSHCT) Lymphoma Working Group. Blood. 2011;118:503a [Abstract #503].
Metadaten
Titel
NK/T-Cell Lymphomas: Pathobiology, Prognosis and Treatment Paradigm
verfasst von
Ritsuro Suzuki
Publikationsdatum
01.10.2012
Verlag
Current Science Inc.
Erschienen in
Current Oncology Reports / Ausgabe 5/2012
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-012-0245-9

Weitere Artikel der Ausgabe 5/2012

Current Oncology Reports 5/2012 Zur Ausgabe

Lymphomas (PA Hamlin, Section Editor)

Novel Agents in Hodgkin Lymphoma

Lymphomas (PA Hamlin, Section Editor)

B-Cell Receptor Pathobiology and Targeting in NHL

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.